Jump to content

Talk:Alexion Pharmaceuticals

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Donating Soliris in Germany

[edit]

...in a rare expression of good will, and hoping for more media attention <g> 46.138.95.18 (talk) 06:36, 6 November 2011 (UTC)[reply]

Alexion Pharmaceuticals page edits

[edit]

Products: Soliris, Kanuma, Strensiq[1]
Revenue: US$ 2.604 bil (2015)[2]
Operating Income: US$ 536.671 mil (2015)[3]
Net income: US$ 144.385 mil (2015)[4]
Total assets: US$ 13.133230 bil (2015)[5]
Total equity: US$ 8.258616 bil (2015)[6]
Number of employees: 3,000 (2015)[7]
Website: www.alexion.com

It also employes about 3,000 people worldwide.[8]

Acquisitions Synageva's main drug, Kanuma, received approval in the United Stations on December 8, 2015 and European approval on September 1, 2015.[9]

The Synageva acquisiton was completed on June 22, 2015.[10]

Kanuma Kanuma is also approved in the European Union[11] and Japan[12].

KateDietz (talk) 20:07, 3 November 2016 (UTC)[reply]

References

  1. ^ "Life-transforming Therapies". www.alexion.com. Retrieved 3 November 2016.
  2. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  3. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  4. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  5. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  6. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  7. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  8. ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
  9. ^ ""European Commission Grants Marketing Authorization for KanumaTM (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)"". www.businesswire.com. Retrieved 3 November 2016.
  10. ^ ""Alexion Completes Acquisition of Synageva"". www.alexion.com. Retrieved 3 November 2016.
  11. ^ "33. "European Commission Grants Marketing Authorization for KanumaTM (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)"". www.businesswire.com. Retrieved 3 November 2016. {{cite web}}: horizontal tab character in |title= at position 4 (help)
  12. ^ ""Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)"". www.alexion.com. Retrieved 3 November 2016.